Home Archives 2011 January

Monthly Archives: January 2011

The February 2011 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:

Volume 17, Issue 1

Editorial

Applying design thinking to biotechnologyPDF
Yali Friedman

Commentary

Building biotechnology by design: An entrepreneur’s perspectivePDF
Arthur A Boni
Building biotechnology by design: Role of biotechnology in developmentPDF
Patrick Nef

Articles

Pricing biologics: Issues, strategic priorities and a conceptual modelPDF
Sanjay K Rao
Revitalizing portfolio decision-making at Merck Serono S.A. – GenevaPDF
Vincent Aurentz, Bernhard Kirschbaum, Markus Thunecke
Global consensus – Need of the hour for genetically modified organisms (GMO) labelingPDF
Jagadeesan Premanandh
Beyond investment: Advancing the biotechnology sector in the countries of the Gulf Cooperation Council (GCC)PDF
Leonard Lerer, Brett Bowman

Case Study

Repurposing of the epidermal growth factorPDF
Ernesto L Mola, José A Buxadó, Luis Herrera
Biotechnology commercialization: A case study from Central and Eastern EuropePDF
Dana Ukropcova, Ernest Sturdik
The developments in the business models of biotechnology in the Central and Eastern European countries: The example of EstoniaPDF
Margit Suurna

Legal and Regulatory Updates

EU Legal and Regulatory UpdatePDF
Gerry Kamstra

I will be teaching Biotechnology Management (TECH 566) again this spring at the National Institutes of Health Foundation for Advanced Education in the Sciences. The focus of this course is on learning the skills necessary to succeed in the biotechnology industry. Classes are comprised of a combination of lectures based on my textbook, Building Biotechnology, and guest lectures from local entrepreneurs, financiers, and biotechnology company management.

Classes start on January 25th, and are held on Tuesday evenings in the NIH Office of Technology Transfer offices. For more details, see TECH 566 in the FAES course catalog.

Drug Patent Expirations in January 2011

*Drugs may be covered by multiple patents

TradenameApplicantGeneric NamePatent Number Patent Expiration
VITRAVENE PRESERVATIVE FREENovartisfomivirsen sodium5,276,019Jan 4, 2011
ELIGARDTolmar Therapleuprolide acetate5,278,201Jan 11, 2011
ULTIVABioniche Teorantaremifentanil hydrochloride5,019,583*PEDJan 12, 2011
XELODAHoffmann La Rochecapecitabine4,966,891Jan 13, 2011
DUETACTTakeda Globalglimepiride; pioglitazone hydrochloride4,687,777Jan 17, 2011
ACTOSTakeda Pharms Napioglitazone hydrochloride4,687,777Jan 17, 2011
ACTOPLUS METTakeda Globalmetformin hydrochloride; pioglitazone hydrochloride4,687,777Jan 17, 2011
ACTOPLUS MET XRTakeda Globalmetformin hydrochloride; pioglitazone hydrochloride4,687,777Jan 17, 2011
PROTONIX IVWyeth Pharms Incpantoprazole sodium4,758,579*PEDJan 19, 2011
PROTONIXWyeth Pharms Incpantoprazole sodium4,758,579*PEDJan 19, 2011
EMENDMerckaprepitant5,145,684Jan 25, 2011
MEGACE ESPar Pharmmegestrol acetate5,145,684Jan 25, 2011
TRICORAbbottfenofibrate5,145,684Jan 25, 2011
VFENDPfizervoriconazole5,773,443Jan 25, 2011
BAYCOLBayer Pharmscerivastatin sodium5,177,080Jan 26, 2011

This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin. Courtesy of DrugPatentWatch.com